Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Apr 15;99(8):1926–1935. doi: 10.1172/JCI119360

Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.

Y H Liu 1, X P Yang 1, V G Sharov 1, O Nass 1, H N Sabbah 1, E Peterson 1, O A Carretero 1
PMCID: PMC508017  PMID: 9109437

Abstract

Angiotensin-converting enzyme inhibitors (ACEi) improve cardiac function and remodeling and prolong survival in patients with heart failure (HF). Blockade of the renin-angiotensin system (RAS) with an angiotensin II type 1 receptor antagonist (AT1-ant) may have a similar beneficial effect. In addition to inhibition of the RAS, ACEi may also act by inhibiting kinin destruction, whereas AT1-ant may block the RAS at the level of the AT1 receptor and activate the angiotensin II type 2 (AT2) receptor. Using a model of HF induced by myocardial infarction (MI) in rats, we studied the role of kinins in the cardioprotective effect of ACEi. We also investigated whether an AT1-ant has a similar effect and whether these effects are partly due to activation of the AT2 receptor. Two months after MI, rats were treated for 2 mo with: (a) vehicle; (b) the ACEi ramipril, with and without the B2 receptor antagonist icatibant (B2-ant); or (c) an AT1-ant with and without an AT2-antagonist (AT2-ant) or B2-ant. Vehicle-treated rats had a significant increase in left ventricular end-diastolic (LVEDV) and end-systolic volume (LVESV) as well as interstitial collagen deposition and cardiomyocyte size, whereas ejection fraction was decreased. Left ventricular remodeling and cardiac function were improved by the ACEi and AT1-ant. The B2-ant blocked most of the cardioprotective effect of the ACEi, whereas the effect of the AT1-ant was blocked by the AT2-ant. The decreases in LVEDV and LVESV caused by the AT1-ant were also partially blocked by the B2-ant. We concluded that (a) in HF both ACEi and AT1-ant have a cardioprotective effect, which could be due to either a direct action on the heart or secondary to altered hemodynamics, or both; and (b) the effect of the ACEi is mediated in part by kinins, whereas that of the AT1-ant is triggered by activation of the AT2 receptor and is also mediated in part by kinins. We speculate that in HF, blockade of AT1 receptors increases both renin and angiotensins; these angiotensins stimulate the AT2 receptor, which in turn may play an important role in the therapeutic effect of the AT1-ant via kinins and other autacoids.

Full Text

The Full Text of this article is available as a PDF (453.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abassi Z. A., Kelly G., Golomb E., Klein H., Keiser H. R. Losartan improves the natriuretic response to ANF in rats with high-output heart failure. J Pharmacol Exp Ther. 1994 Jan;268(1):224–230. [PubMed] [Google Scholar]
  2. Aceto J. F., Baker K. M. [Sar1]angiotensin II receptor-mediated stimulation of protein synthesis in chick heart cells. Am J Physiol. 1990 Mar;258(3 Pt 2):H806–H813. doi: 10.1152/ajpheart.1990.258.3.H806. [DOI] [PubMed] [Google Scholar]
  3. Baker K. M., Aceto J. F. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol. 1990 Aug;259(2 Pt 2):H610–H618. doi: 10.1152/ajpheart.1990.259.2.H610. [DOI] [PubMed] [Google Scholar]
  4. Brosnihan K. B., Li P., Ferrario C. M. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996 Mar;27(3 Pt 2):523–528. doi: 10.1161/01.hyp.27.3.523. [DOI] [PubMed] [Google Scholar]
  5. Campbell D. J., Kladis A., Duncan A. M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension. 1994 Apr;23(4):439–449. doi: 10.1161/01.hyp.23.4.439. [DOI] [PubMed] [Google Scholar]
  6. Campbell D. J., Kladis A., Valentijn A. J. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol. 1995 Aug;26(2):233–240. doi: 10.1097/00005344-199508000-00009. [DOI] [PubMed] [Google Scholar]
  7. Carini D. J., Duncia J. V., Aldrich P. E., Chiu A. T., Johnson A. L., Pierce M. E., Price W. A., Santella J. B., 3rd, Wells G. J., Wexler R. R. Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives. J Med Chem. 1991 Aug;34(8):2525–2547. doi: 10.1021/jm00112a031. [DOI] [PubMed] [Google Scholar]
  8. Cohn J. N. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation. 1995 May 15;91(10):2504–2507. doi: 10.1161/01.cir.91.10.2504. [DOI] [PubMed] [Google Scholar]
  9. Dahlöf B. Regression of left ventricular hypertrophy--are there differences between antihypertensive agents? Cardiology. 1992;81(4-5):307–315. doi: 10.1159/000175821. [DOI] [PubMed] [Google Scholar]
  10. Dickstein K., Chang P., Willenheimer R., Haunsø S., Remes J., Hall C., Kjekshus J. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 1995 Aug;26(2):438–445. doi: 10.1016/0735-1097(95)80020-h. [DOI] [PubMed] [Google Scholar]
  11. Dickstein K., Gottlieb S., Fleck E., Kostis J., Levine B., DeKock M., LeJemtel T. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J Hypertens Suppl. 1994 Jul;12(2):S31–S35. [PubMed] [Google Scholar]
  12. Everett A. D., Tufro-McReddie A., Fisher A., Gomez R. A. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. Hypertension. 1994 May;23(5):587–592. doi: 10.1161/01.hyp.23.5.587. [DOI] [PubMed] [Google Scholar]
  13. Farhy R. D., Carretero O. A., Ho K. L., Scicli A. G. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res. 1993 Jun;72(6):1202–1210. doi: 10.1161/01.res.72.6.1202. [DOI] [PubMed] [Google Scholar]
  14. Fletcher P. J., Pfeffer J. M., Pfeffer M. A., Braunwald E. Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction. Effects on systolic function. Circ Res. 1981 Sep;49(3):618–626. doi: 10.1161/01.res.49.3.618. [DOI] [PubMed] [Google Scholar]
  15. Ganz M. B., Perfetto M. C., Boron W. F. Effects of mitogens and other agents on rat mesangial cell proliferation, pH, and Ca2+. Am J Physiol. 1990 Aug;259(2 Pt 2):F269–F278. doi: 10.1152/ajprenal.1990.259.2.F269. [DOI] [PubMed] [Google Scholar]
  16. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995 May 10;273(18):1450–1456. [PubMed] [Google Scholar]
  17. Gavras H., Faxon D. P., Berkoben J., Brunner H. R., Ryan T. J. Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation. 1978 Nov;58(5):770–776. doi: 10.1161/01.cir.58.5.770. [DOI] [PubMed] [Google Scholar]
  18. Gavras H., Gavras I. Cardioprotective potential of angiotensin converting enzyme inhibitors. J Hypertens. 1991 May;9(5):385–392. doi: 10.1097/00004872-199105000-00001. [DOI] [PubMed] [Google Scholar]
  19. Gavras I., Manolis A., Gavras H. Effects of ACE inhibition on the heart. J Hum Hypertens. 1995 Jun;9(6):455–458. [PubMed] [Google Scholar]
  20. Gohlke P., Linz W., Schölkens B. A., Kuwer I., Bartenbach S., Schnell A., Unger T. Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension. 1994 Apr;23(4):411–418. doi: 10.1161/01.hyp.23.4.411. [DOI] [PubMed] [Google Scholar]
  21. Gottlieb S. S., Dickstein K., Fleck E., Kostis J., Levine T. B., LeJemtel T., DeKock M. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993 Oct;88(4 Pt 1):1602–1609. doi: 10.1161/01.cir.88.4.1602. [DOI] [PubMed] [Google Scholar]
  22. Hansen-Smith F. M., Watson L., Lu D. Y., Goldstein I. Griffonia simplicifolia I: fluorescent tracer for microcirculatory vessels in nonperfused thin muscles and sectioned muscle. Microvasc Res. 1988 Nov;36(3):199–215. doi: 10.1016/0026-2862(88)90022-2. [DOI] [PubMed] [Google Scholar]
  23. Hartman J. C., Wall T. M., Hullinger T. G., Shebuski R. J. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol. 1993 Jun;21(6):996–1003. doi: 10.1097/00005344-199306000-00022. [DOI] [PubMed] [Google Scholar]
  24. Hecker M., Pörsti I., Busse R. Mechanisms involved in the angiotensin II-independent hypotensive action of ACE inhibitors. Braz J Med Biol Res. 1994 Aug;27(8):1917–1921. [PubMed] [Google Scholar]
  25. Ichiki T., Labosky P. A., Shiota C., Okuyama S., Imagawa Y., Fogo A., Niimura F., Ichikawa I., Hogan B. L., Inagami T. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature. 1995 Oct 26;377(6551):748–750. doi: 10.1038/377748a0. [DOI] [PubMed] [Google Scholar]
  26. Laitinen L. Griffonia simplicifolia lectins bind specifically to endothelial cells and some epithelial cells in mouse tissues. Histochem J. 1987 Apr;19(4):225–234. doi: 10.1007/BF01680633. [DOI] [PubMed] [Google Scholar]
  27. Lamontagne D., Nadeau R., Adam A. Effect of enalaprilat on bradykinin and des-Arg9-bradykinin release following reperfusion of the ischaemic rat heart. Br J Pharmacol. 1995 Jun;115(3):476–478. doi: 10.1111/j.1476-5381.1995.tb16357.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Liebson P. R., Grandits G. A., Dianzumba S., Prineas R. J., Grimm R. H., Jr, Neaton J. D., Stamler J. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1995 Feb 1;91(3):698–706. doi: 10.1161/01.cir.91.3.698. [DOI] [PubMed] [Google Scholar]
  29. Lindpaintner K., Ganten D. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ Res. 1991 Apr;68(4):905–921. doi: 10.1161/01.res.68.4.905. [DOI] [PubMed] [Google Scholar]
  30. Linz W., Schölkens B. A. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol. 1992;20 (Suppl 9):S83–S90. [PubMed] [Google Scholar]
  31. Linz W., Wiemer G., Schölkens B. A. Bradykinin prevents left ventricular hypertrophy in rats. J Hypertens Suppl. 1993 Dec;11(5):S96–S97. [PubMed] [Google Scholar]
  32. Liu Y. H., Yang X. P., Nass O., Sabbah H. N., Peterson E., Carretero O. A. Chronic heart failure induced by coronary artery ligation in Lewis inbred rats. Am J Physiol. 1997 Feb;272(2 Pt 2):H722–H727. doi: 10.1152/ajpheart.1997.272.2.H722. [DOI] [PubMed] [Google Scholar]
  33. Liu Y. H., Yang X. P., Sharov V. G., Sigmon D. H., Sabbath H. N., Carretero O. A. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension. 1996 Jan;27(1):7–13. doi: 10.1161/01.hyp.27.1.7. [DOI] [PubMed] [Google Scholar]
  34. Lo M., Liu K. L., Lantelme P., Sassard J. Subtype 2 of angiotensin II receptors controls pressure-natriuresis in rats. J Clin Invest. 1995 Mar;95(3):1394–1397. doi: 10.1172/JCI117792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Lopez J. J., Lorell B. H., Ingelfinger J. R., Weinberg E. O., Schunkert H., Diamant D., Tang S. S. Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol. 1994 Aug;267(2 Pt 2):H844–H852. doi: 10.1152/ajpheart.1994.267.2.H844. [DOI] [PubMed] [Google Scholar]
  36. McDonald K. M., Garr M., Carlyle P. F., Francis G. S., Hauer K., Hunter D. W., Parish T., Stillman A., Cohn J. N. Relative effects of alpha 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation. 1994 Dec;90(6):3034–3046. doi: 10.1161/01.cir.90.6.3034. [DOI] [PubMed] [Google Scholar]
  37. McDonald K. M., Mock J., D'Aloia A., Parrish T., Hauer K., Francis G., Stillman A., Cohn J. N. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation. 1995 Apr 1;91(7):2043–2048. doi: 10.1161/01.cir.91.7.2043. [DOI] [PubMed] [Google Scholar]
  38. Minshall R. D., Nakamura F., Becker R. P., Rabito S. F. Characterization of bradykinin B2 receptors in adult myocardium and neonatal rat cardiomyocytes. Circ Res. 1995 May;76(5):773–780. doi: 10.1161/01.res.76.5.773. [DOI] [PubMed] [Google Scholar]
  39. Nakajima M., Hutchinson H. G., Fujinaga M., Hayashida W., Morishita R., Zhang L., Horiuchi M., Pratt R. E., Dzau V. J. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10663–10667. doi: 10.1073/pnas.92.23.10663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Nio Y., Matsubara H., Murasawa S., Kanasaki M., Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest. 1995 Jan;95(1):46–54. doi: 10.1172/JCI117675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Nolly H., Carbini L. A., Scicli G., Carretero O. A., Scicli A. G. A local kallikrein-kinin system is present in rat hearts. Hypertension. 1994 Jun;23(6 Pt 2):919–923. doi: 10.1161/01.hyp.23.6.919. [DOI] [PubMed] [Google Scholar]
  42. Nolly H., Carretero O. A., Scicli A. G. Kallikrein release by vascular tissue. Am J Physiol. 1993 Oct;265(4 Pt 2):H1209–H1214. doi: 10.1152/ajpheart.1993.265.4.H1209. [DOI] [PubMed] [Google Scholar]
  43. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  44. Rhaleb N. E., Yang X. P., Scicli A. G., Carretero O. A. Role of kinins and nitric oxide in the antihypertrophic effect of ramipril. Hypertension. 1994 Jun;23(6 Pt 2):865–868. doi: 10.1161/01.hyp.23.6.865. [DOI] [PubMed] [Google Scholar]
  45. Sadoshima J., Xu Y., Slayter H. S., Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993 Dec 3;75(5):977–984. doi: 10.1016/0092-8674(93)90541-w. [DOI] [PubMed] [Google Scholar]
  46. Saitoh S., Scicli A. G., Peterson E., Carretero O. A. Effect of inhibiting renal kallikrein on prostaglandin E2, water, and sodium excretion. Hypertension. 1995 May;25(5):1008–1013. doi: 10.1161/01.hyp.25.5.1008. [DOI] [PubMed] [Google Scholar]
  47. Seyedi N., Xu X., Nasjletti A., Hintze T. H. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 1995 Jul;26(1):164–170. doi: 10.1161/01.hyp.26.1.164. [DOI] [PubMed] [Google Scholar]
  48. Seyedi N., Xu X., Nasjletti A., Hintze T. H. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 1995 Jul;26(1):164–170. doi: 10.1161/01.hyp.26.1.164. [DOI] [PubMed] [Google Scholar]
  49. Sharpe N., Murphy J., Smith H., Hannan S. Preventive treatment of asymptomatic left ventricular dysfunction following myocardial infarction. Eur Heart J. 1990 Apr;11 (Suppl B):147–156. doi: 10.1093/eurheartj/11.suppl_b.147. [DOI] [PubMed] [Google Scholar]
  50. Siragy H. M., Carey R. M. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3', 5'-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats. J Clin Invest. 1996 Apr 15;97(8):1978–1982. doi: 10.1172/JCI118630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Stauss H. M., Zhu Y. C., Redlich T., Adamiak D., Mott A., Kregel K. C., Unger T. Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. J Cardiovasc Risk. 1994 Oct;1(3):255–262. doi: 10.1177/174182679400100311. [DOI] [PubMed] [Google Scholar]
  52. Stoll M., Steckelings U. M., Paul M., Bottari S. P., Metzger R., Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995 Feb;95(2):651–657. doi: 10.1172/JCI117710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Suzuki J., Matsubara H., Urakami M., Inada M. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res. 1993 Sep;73(3):439–447. doi: 10.1161/01.res.73.3.439. [DOI] [PubMed] [Google Scholar]
  54. Tomiyama H., Scicli A. G., Scicli G. M., Carretero O. A. Renal effects of Fab fragments of kinin antibodies on deoxycorticosterone acetate-salt-treated rats. Hypertension. 1990 Jun;15(6 Pt 2):761–766. doi: 10.1161/01.hyp.15.6.761. [DOI] [PubMed] [Google Scholar]
  55. Whitebread S., Mele M., Kamber B., de Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun. 1989 Aug 30;163(1):284–291. doi: 10.1016/0006-291x(89)92133-5. [DOI] [PubMed] [Google Scholar]
  56. Yang X. P., Sabbah H. N., Liu Y. H., Sharov V. G., Mascha E. J., Alwan I., Carretero O. A. Ventriculographic evaluation in three rat models of cardiac dysfunction. Am J Physiol. 1993 Dec;265(6 Pt 2):H1946–H1952. doi: 10.1152/ajpheart.1993.265.6.H1946. [DOI] [PubMed] [Google Scholar]
  57. van Gilst W. H., Tio R. A., van Wijngaarden J., de Graeff P. A., Wesseling H. Effects of converting enzyme inhibitors on coronary flow and myocardial ischemia. J Cardiovasc Pharmacol. 1992;19 (Suppl 5):S134–S139. [PubMed] [Google Scholar]
  58. von Lutterotti N., Catanzaro D. F., Sealey J. E., Laragh J. H. Renin is not synthesized by cardiac and extrarenal vascular tissues. A review of experimental evidence. Circulation. 1994 Jan;89(1):458–470. doi: 10.1161/01.cir.89.1.458. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES